Latest News

The standard-of-care first-line systemic therapy for metastatic urothelial cancer (mUC) remains platinum-based chemotherapy. Post-platinum options included immune checkpoint inhibitors, fibroblast growth factor receptor (FGFR) inhibitors in patients with FGFR2 or FGFR3 genomic alterations, or antibody-drug conjugates. However, the best sequence of these systemic therapies is unknown. Furthermore, it is unclear if patients with FGFR2 or […]

Proper tensioning of a mid-urethral sling during surgery is critically important. An excessively tight sling can result urinary retention on one end, while a loose sling can lead to persistent stress incontinence on the other. Either situation is less than ideal and can cause much distress to both the patient and the surgeon.

We dutifully published our experience as the leading centre in the UK employing the NeuroSAFE technique in the National Health Service. This was pioneered by the Martini Klinik group in Hamburg, Germany and they have achieved success in >10,000 nerve spare radical prostatectomies using both open and robotic approaches. Our study’s limitation of an unmatched […]

Reno, Nevada (UroToday.com) — Lantheus Holdings, Inc., an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today that data from the OSPREY pivotal trial has been selected for presentation at the upcoming 2022 American Society for Clinical Oncology […]

CNS germ cell tumors (GCTs) predominantly develop in pediatric and young adult patients with variable responses to surgery, radiation, and chemotherapy. This study aimed to examine the complex and largely unknown pathogenesis of CNS GCTs.

Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy is frequently used off-label for clear cell metastatic renal cell carcinoma (mRCC). However, limited data are available to guide such therapy.

The aim of this retrospective study was to elucidate predictors of survival in metastatic renal cell carcinoma (mRCC) patients in an International Metastatic Renal Cell Carcinoma Database Consortium favorable risk group treated with frontline therapy without immune checkpoint inhibitors.

Existing measures of sexual functioning in prostate cancer survivors focus primarily on erectile function and do not adequately measure the experiences of sexual minority men. To develop and psychometrically evaluate a new scale to measure sexual functioning among sexual minority men with prostate cancer.

The objective of the study is to identify the rate of significant prostate cancer (PCa) detection in PI-RADS3 lesions in AA patients stratified by PSAD threshold of < 0.15 vs. ≥ 0.

Prostate-specific antigen (PSA) secretion is a testosterone (T) dependent process. Published data suggest that a low T level is an independent predictor of higher-grade prostate cancer (PC). To evaluate the relationship between T and PSA in patients with PC.